Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Significant Drop in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 45,540 shares, a decrease of 63.2% from the November 30th total of 123,591 shares. Based on an average daily volume of 218,008 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 218,008 shares, the short-interest ratio is currently 0.2 days.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of OTCMKTS:SGIOY traded up $0.17 during midday trading on Friday, reaching $9.05. 58,010 shares of the company’s stock were exchanged, compared to its average volume of 102,712. The firm has a market capitalization of $15.40 billion, a PE ratio of 14.14, a price-to-earnings-growth ratio of 2.10 and a beta of 0.20. The company’s 50 day simple moving average is $8.49 and its two-hundred day simple moving average is $8.59. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $6.71 and a 12 month high of $9.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.74 and a current ratio of 6.44.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its earnings results on Monday, October 27th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.02. The business had revenue of $740.85 million for the quarter, compared to analyst estimates of $742.35 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 11.90%. Equities research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.